Who We Are
- About Us
  
  About Us
  
  Learn more about who we are and what we aim to accomplish for patients with chronic eye diseases.
- Management
  
  Management
  
  Meet our team of experienced leaders.
- Board of Directors
  
  Board of Directors
  
  Meet the members of our Board of Directors.
- Scientific Advisory Board
  
  Scientific Advisory Board
  
  Meet the members of our Scientific Advisory Board.
- Our DNA
  
  Our DNA
  
  Learn more about our history.
What We Solve For
- What We Solve For
  
  What We Solve For
  
  For people with chronic diseases of the retina and the optic nerve, we develop medicines that make healthy vision more accessible and manageable, promoting better compliance and visual outcomes.
- Retinal Diseases
  
  Retinal Diseases
  
  For people with chronic diseases of the retina and the optic nerve, we develop medicines that make healthy vision more accessible and manageable, promoting better compliance and visual outcomes.
- Glaucoma
  
  Glaucoma
  
  Glaucoma is characterized by the progressive degeneration of the optic nerve, leading to visual impairment. Primary open angle glaucoma is the most common type of glaucoma. Learn more about what happens in the eye, unmet needs and potential solutions.
Our Technologies and Pipeline
- Our Technologies
  
  Our Technologies
  
  Our proprietary technologies are designed to allow sustained delivery of pharmacologic agents to the eye in a well-controlled and tolerable manner to achieve extended duration of effectiveness. Learn more about how it works.
- Our Pipeline
  
  Our Pipeline
  
  Our pipeline leverages Graybug’s proprietary technologies with the goal of improving patient compliance, reducing healthcare burdens and ultimately improving clinical outcomes.
  - GB-102
    
    GB-102
    
    We are developing GB-102 as a twice-per-year intravitreal pan-VEGF inhibitor for the treatment of wet AMD and DME.
  - GB-103
    
    GB-103
    
    We are developing GB-103 as a once-per-year intravitreal pan-VEGF inhibitor for the treatment of diabetic retinopathy.
  - GB-401
    
    GB-401
    
    We are developing GB-401 as a twice-per-year intravitreal beta-blocker for the treatment of primary open angle glaucoma.
- Medical Events & Publications
  
  Medical Events & Publications
Investors and Media
- Overview
  
  Overview
  
  One-stop-shop for Graybug News and Events, Corporate Governance, Stock Information, Financials, Filings and Resources.
- News and Events
  News and Events
  Press Releases
  
  Press Releases
  
  IR Events & Presentations
  
  IR Events & Presentations
  
  Medical Events & Publications
  
  Medical Events & Publications
- Corporate Governance
  Corporate Governance
  Board Documents & Charters
  
  Board Documents & Charters
  
  Board Committee Composition
  
  Board Committee Composition
  
  Management Team
  
  Management Team
  
  Board of Directors
  
  Board of Directors
- Stock Information
  Stock Information
  Stock Quote & Chart
  
  Stock Quote & Chart
  
  Historic Price Lookup
  
  Historic Price Lookup
  
  Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin vitae elit a neque vestibulum hendrerit. Nunc eget porttitor diam. Quisque ac diam erat.
  
  Investment Calculator
  
  Investment Calculator
  
  Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin vitae elit a neque vestibulum hendrerit. Nunc eget porttitor diam.
  
  Analyst Coverage
  
  Analyst Coverage
- Financials and Filings
  Financials and Filings
  SEC Filings
  
  SEC Filings
  
  Annual Reports and Proxy Statements
  
  Annual Reports and Proxy Statements
- Resources
  Resources
  Email Alerts
  
  Email Alerts
  
  Information Request
  
  Information Request
  
  Investor FAQs
  
  Investor FAQs
Join Us
Contact Us
LinkedIn